Addressing demand for recombinant biopharmaceuticals in the COVID-19 era

来源 :亚太热带医药杂志(英文版) | 被引量 : 0次 | 上传用户:xiaobailxiaoyi
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
1. COVID-19 pandemicrnThe emergence and re-emergence of infectious diseases in recent years demand national health care systems to develop effective surveillance mechanisms, diagnostic, treatment, and preventive strategies. The last two decades witnessed the outbreak of several viral infections with epidemic and pandemic potentials, most of which are zoonotic. These include severe acute respiratory syndrome-coronavirus (SARS-CoV), avian and swine-origin influenza viruses, Middle East respiratory syndrome-coronavirus, Ebola, Chikungunya, Zika, Nipah, and, more recently, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)[1]. SARS-CoV-2 represents family Coronaviridae, subfamily Orthocoronavirinae, and genus Betacoronavirus. By early November 2020, there have been more than 50 million confirmed cases of COVID-19 globally, with over 1 million reported deaths[2]. The ability of the virus to spread from person to person and the mortality associated with the infection pose serious threats to public health globally. The outbreak also had a major impact on global economy and lifestyle of human populations. The pathogenesis and transmission cycle of SARS-CoV-2 has not been elucidated completely, which hampers the development of effective treatment and preventive measures.
其他文献
根据今日投资《在线分析师》(www.investoday.com.cn)对国内近百家主流研究机构4000余名分析师的投资评级数据进行的统计,上周投资评级上调居前的25只股票中,机械制造行业录
会议
会议
会议
会议
会议
会议
会议
会议
会议